In the last few decades, therapeutic strategies that target the specific molecules responsible for the initiation or amplification of cancer progression have shown great success. Many cancers, however, have evolved into highly heterogeneous and therapy-resistant malignant diseases with an inflammatory origin. As such, the concept of multitarget drugs has emerged as a promising therapeutic strategy to effectively tackle chronic inflammatory diseases, including cancers.1
GlycoMira’s lead asset – GM-1111 – inhibits multiple molecular factors in the tumor microenvironment that contribute to the development and growth of solid tumors, as well as treatment-resistant cancers.2 GM-1111 targets innate immune receptors that initiate and amplify inflammatory processes in the tumor to reduce the release and accumulation of molecular factors and immune cells essential for tumor growth. Emerging evidence also suggests that GM-1111 directly inhibits the growth of cancer stem cells, which contribute to chemoradiation therapy resistance and cancer relapse. Simultaneous action against these molecular and cellular components will ultimately lead to the enhancement of cancer therapy efficacy and outcomes for patients.